BRPI0715580A2 - ''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO'' - Google Patents

''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO''

Info

Publication number: BRPI0715580A2
Authority: BR; Brazil
Prior art keywords: antibody; linfotoxin; lta; isolated; hydrople
Prior art date: 2006-10-12

Application number

BRPI0715580-8A2A

Other languages

English (en)

Inventor

Camellia W Adams

Jane L Grogan

Austin L Gurney

Krista Mccutcheon

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-12

Filing date

2007-10-11

Publication date

2014-06-10

2007-10-11 Application filed by Genentech Inc filed Critical Genentech Inc

2014-06-10 Publication of BRPI0715580A2 publication Critical patent/BRPI0715580A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
General Physics & Mathematics (AREA)
Hematology (AREA)
Theoretical Computer Science (AREA)
Rheumatology (AREA)
General Business, Economics & Management (AREA)
Physics & Mathematics (AREA)
Business, Economics & Management (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)

BRPI0715580-8A2A 2006-10-12 2007-10-11 ''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO'' BRPI0715580A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82925706P	2006-10-12	2006-10-12
US93899907P	2007-05-18	2007-05-18
PCT/US2007/081154 WO2008063776A2 (en)	2006-10-12	2007-10-11	Antibodies to lymphotoxin-alpha

Publications (1)

Publication Number	Publication Date
BRPI0715580A2 true BRPI0715580A2 (pt)	2014-06-10

Family

ID=39430415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0715580-8A2A BRPI0715580A2 (pt)	2006-10-12	2007-10-11	''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO''

Country Status (21)

Country	Link
US (4)	US7923011B2 (pt)
EP (1)	EP2084188A2 (pt)
JP (1)	JP5298021B2 (pt)
KR (1)	KR20090078349A (pt)
AR (1)	AR063257A1 (pt)
AU (1)	AU2007324135B2 (pt)
BR (1)	BRPI0715580A2 (pt)
CA (1)	CA2665644A1 (pt)
CL (1)	CL2007002926A1 (pt)
CO (1)	CO6220841A2 (pt)
CR (1)	CR10705A (pt)
IL (1)	IL197937A0 (pt)
MA (1)	MA30876B1 (pt)
MX (1)	MX2009003774A (pt)
NO (1)	NO20091841L (pt)
NZ (1)	NZ576032A (pt)
PE (1)	PE20080980A1 (pt)
RU (1)	RU2486201C2 (pt)
TW (1)	TWI414531B (pt)
UA (1)	UA94484C2 (pt)
WO (1)	WO2008063776A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010036443A1 (en) *	2008-09-26	2010-04-01	Eureka Therapeutics, Inc.	Cell lines and proteins with variant glycosylation pattern
JP2012504245A (ja) *	2008-09-30	2012-02-16	ジェネンテック，インコーポレイテッド	リンホトキシンアンタゴニストに対する関節リウマチの応答性を予測する生物学的マーカー
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011060015A1 (en)	2009-11-11	2011-05-19	Genentech, Inc.	Methods and compositions for detecting target proteins
CN102958537B (zh) *	2010-04-07	2015-09-16	Abbvie公司	TNF-α结合蛋白
US8858944B2 (en)	2010-06-02	2014-10-14	Sumitomo Dainippon Pharma Co., Ltd.	Treatment drug for autoimmune diseases and allergic diseases
CN102621310B (zh) *	2011-01-28	2014-07-02	上海科新生物技术股份有限公司	胶体金层析法抗u1-rnp抗体检测试纸及其制备方法
KR20130036993A (ko) *	2011-10-05	2013-04-15	삼성전자주식회사	ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013114164A1 (en) *	2012-01-30	2013-08-08	Dr. Reddy's Laboratories Limited	Method for obtaining glycoprotein composition with increased afucosylation content
AU2013266611B2 (en)	2012-05-21	2016-08-11	Genentech, Inc.	Methods for improving safety of blood-brain barrier transport
US12565524B2 (en) *	2012-05-29	2026-03-03	North Carolina Central University	Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues
GB201314052D0 (en)	2013-08-06	2013-09-18	Apitope Int Nv	Peptides
EP2935611B1 (en) *	2013-10-14	2021-07-07	SynAffix B.V.	Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057906A1 (en) *	2013-10-16	2015-04-23	Janssen Biotech, Inc.	Cd200 receptor 1 agonists
KR101820572B1 (ko) *	2015-08-12	2018-01-19	가톨릭대학교 산학협력단	만성골수성백혈병에 관한 정보 제공 방법
CN108431026B (zh)	2015-11-02	2023-02-17	豪夫迈·罗氏有限公司	制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
JP7672196B2 (ja)	2017-03-14	2025-05-07	アムジエン・インコーポレーテツド	細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
US12054558B2 (en)	2018-05-23	2024-08-06	The Jackson Laboratory	Anti-NGly-1 antibodies and methods of use
US12365720B2 (en) *	2018-11-16	2025-07-22	Consejo Superior De Investigaciones Cientificas	Etanercept variants with improved therapeutical effect
CN111285936A (zh) *	2020-03-11	2020-06-16	北京双赢科创生物科技有限公司	靶向肿瘤的酸性敏感纳米肽段及其应用
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4920196A (en)	1982-07-30	1990-04-24	Genentech, Inc.	Human lymphotoxin
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
NZ212207A (en) *	1984-05-31	1991-07-26	Genentech Inc	Recombinant lymphotoxin
US4959457A (en)	1984-05-31	1990-09-25	Genentech, Inc.	Anti-lymphotoxin
US5683688A (en)	1984-05-31	1997-11-04	Genentech, Inc.	Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
ES2058199T3 (es)	1987-09-23	1994-11-01	Bristol Myers Squibb Co	Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
JPH023698A (ja)	1988-06-20	1990-01-09	Denki Kagaku Kogyo Kk	ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6475787B1 (en)	1989-07-28	2002-11-05	Wyeth	Method for producing monoclonal antibodies
NZ235148A (en)	1989-09-05	1991-12-23	Immunex Corp	Tumour necrosis factor receptor protein and dna sequences
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
ATE201879T1 (de)	1990-06-27	2001-06-15	Biogen Inc	Oberflächenkomplexbildung von lymphotoxin
US7030080B2 (en)	1990-06-27	2006-04-18	Biogen, Inc.	Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5795964A (en)	1990-06-27	1998-08-18	Biogen, Inc.	Lymphotoxin-beta and lymphotoxin-beta complexes
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
ES2108048T3 (es)	1990-08-29	1997-12-16	Genpharm Int	Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en)	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
ATE414768T1 (de)	1991-04-10	2008-12-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
EP0604580A1 (en)	1991-09-19	1994-07-06	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
RU2048521C1 (ru) *	1992-05-25	1995-11-20	Научно-Исследовательский Конструкторско-Технологический Институт Биологически Активных Веществ	Способ получения полипептида со свойствами лимфотоксина человека
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US20050260201A1 (en)	1993-01-29	2005-11-24	Centocor, Inc.	Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
US5747023A (en)	1994-07-01	1998-05-05	Genentech, Inc.	Cancer therapy using lymphotoxin
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US6312691B1 (en)	1996-01-26	2001-11-06	Jeffrey L. Browning	Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5837234A (en)	1995-06-07	1998-11-17	Cytotherapeutics, Inc.	Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5925351A (en)	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6027888A (en)	1996-04-05	2000-02-22	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US5747373A (en) *	1996-09-24	1998-05-05	Taiwan Semiconductor Manufacturing Company Ltd.	Nitride-oxide sidewall spacer for salicide formation
NZ335353A (en)	1996-10-25	2000-09-29	Biogen Inc	Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
US7255854B1 (en)	1996-10-25	2007-08-14	Biogen, Inc.	Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6528624B1 (en)	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
ES2434961T5 (es)	1998-04-20	2018-01-18	Roche Glycart Ag	Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CA2338981A1 (en)	1998-07-29	2000-02-10	Kyowa Hakko Kogyo Co., Ltd.	.alpha.1,3-fucosyltransferase nucleic acid and polypeptide
TR200504220T2 (tr)	1998-12-17	2007-04-24	Biogen Idec Ma Inc.	Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
KR101077001B1 (ko) *	1999-01-15	2011-10-26	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
AU756677B2 (en)	1999-03-02	2003-01-23	Centocor Inc.	Anti-TNFalpha antibodies in therapy of asthma
EP1176195B1 (en)	1999-04-09	2013-05-22	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
AU7950400A (en)	1999-10-19	2001-04-30	Kyowa Hakko Kogyo Co. Ltd.	Process for producing polypeptide
US7056695B2 (en)	2000-03-02	2006-06-06	Xencor	TNF-α variants
ES2637801T3 (es)	2000-04-11	2017-10-17	Genentech, Inc.	Anticuerpos multivalentes y usos de los mismos
DE60143798D1 (de) *	2000-06-16	2011-02-17	Cambridge Antibody Tech	Immunspezifisch bindende antikörper gegen blys
US20060029604A1 (en)	2000-06-28	2006-02-09	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7449308B2 (en)	2000-06-28	2008-11-11	Glycofi, Inc.	Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20060034828A1 (en)	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
AU2001276842B2 (en)	2000-06-28	2007-04-26	Glycofi, Inc.	Methods for producing modified glycoproteins
US20060034830A1 (en)	2000-06-28	2006-02-16	Gerngross Tillman U	Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EE200300179A (et)	2000-10-13	2003-08-15	Biogen, Inc.	Humaniseeritud LT-ß-R-i vastased antikehad
JP4731793B2 (ja)	2000-12-28	2011-07-27	アルセアテクノロジーズインコーポレイテッド	抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
US20050271663A1 (en)	2001-06-28	2005-12-08	Domantis Limited	Compositions and methods for treating inflammatory disorders
AU2002363354A1 (en)	2001-07-27	2003-05-19	Human Genome Sciences, Inc.	Heteromultimeric tnf ligand family members
RU2321630C2 (ru)	2001-08-03	2008-04-10	Гликарт Биотекнолоджи АГ	Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en)	2001-10-25	2003-08-21	Genentech, Inc.	Glycoprotein compositions
WO2003047510A2 (en)	2001-11-30	2003-06-12	Centocor, Inc.	Anti-tnf antibodies, compositions, methods and uses
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US7273707B2 (en)	2002-02-08	2007-09-25	Wyeth	Method of identifying a modulator of a LTβR complex signaling pathway
CN102911987B (zh)	2002-04-09	2015-09-30	协和发酵麒麟株式会社	基因组被修饰的细胞
US20050031613A1 (en)	2002-04-09	2005-02-10	Kazuyasu Nakamura	Therapeutic agent for patients having human FcgammaRIIIa
AU2003236018A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2003084569A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Drug containing antibody composition
US20040132140A1 (en)	2002-04-09	2004-07-08	Kyowa Hakko Kogyo Co., Ltd.	Production process for antibody composition
JP4628679B2 (ja)	2002-04-09	2011-02-09	協和発酵キリン株式会社	Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
AU2003234706A1 (en)	2002-04-15	2003-11-03	Human Genome Sciences, Inc.	Antibodies that specifically bind to tl5
CA2491480A1 (en)	2002-07-01	2004-01-08	Biogen, Inc.	Humanized anti-lymphotoxin beta receptor antibodies
US6873910B2 (en) *	2002-10-22	2005-03-29	Qualcomm Incorporated	Procedure for searching for position determination signals using a plurality of search modes
EP1565214A2 (en)	2002-10-31	2005-08-24	Biogen Idec MA Inc.	Treatment of immunological renal disorders by lymphotoxin pathway inhibitors
ES2347241T3 (es)	2002-12-16	2010-10-27	Genentech, Inc.	Variantes de inmunoglobulina y sus utilizaciones.
CN1753692A (zh)	2002-12-20	2006-03-29	比奥根艾迪克Ma公司	淋巴毒素β受体药剂与化疗剂的联合用药
AU2004218354B2 (en)	2003-03-05	2009-10-01	Halozyme, Inc.	Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
NZ545776A (en)	2003-08-22	2009-05-31	Biogen Idec Inc	Improved antibodies having altered effector function and methods for making the same
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
US20070134759A1 (en)	2003-10-09	2007-06-14	Harue Nishiya	Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ES2672640T3 (es)	2003-11-05	2018-06-15	Roche Glycart Ag	Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
KR100772800B1 (ko)	2003-11-17	2007-11-01	주식회사유한양행	인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
US20050266004A1 (en)	2003-12-08	2005-12-01	Jill Giles-Komar	Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
RU2386638C2 (ru)	2004-03-31	2010-04-20	Дженентек, Инк.	Гуманизированные анти-тфр-бета-антитела
WO2006014726A2 (en)	2004-07-21	2006-02-09	Glycofi, Inc.	Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP1771479A1 (en)	2004-07-21	2007-04-11	Glycofi, Inc.	IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlCNACMAN5GLCNAC2 GLYCOFORM
EP1771477A2 (en)	2004-07-21	2007-04-11	Glycofi, Inc.	Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
AU2005269765A1 (en)	2004-07-21	2006-02-09	Glycofi, Inc.	Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform
AU2005269759A1 (en)	2004-07-21	2006-02-09	Glycofi, Inc.	Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060067930A1 (en)	2004-08-19	2006-03-30	Genentech, Inc.	Polypeptide variants with altered effector function
JP2006228261A (ja)	2005-02-15	2006-08-31	Micron Technology Inc	デジット線絶縁ゲートの負電圧駆動
WO2007039818A2 (en)	2005-05-09	2007-04-12	Glycart Biotechnology Ag	Antigen binding molecules having modified fc regions and altered binding to fc receptors

2007
- 2007-10-11 EP EP07871155A patent/EP2084188A2/en not_active Withdrawn
- 2007-10-11 TW TW096138038A patent/TWI414531B/zh not_active IP Right Cessation
- 2007-10-11 US US11/871,136 patent/US7923011B2/en not_active Expired - Fee Related
- 2007-10-11 RU RU2009117680/10A patent/RU2486201C2/ru not_active IP Right Cessation
- 2007-10-11 PE PE2007001374A patent/PE20080980A1/es not_active Application Discontinuation
- 2007-10-11 WO PCT/US2007/081154 patent/WO2008063776A2/en not_active Ceased
- 2007-10-11 CL CL200702926A patent/CL2007002926A1/es unknown
- 2007-10-11 AR ARP070104513A patent/AR063257A1/es not_active Application Discontinuation
- 2007-10-11 KR KR1020097009641A patent/KR20090078349A/ko not_active Ceased
- 2007-10-11 CA CA002665644A patent/CA2665644A1/en not_active Abandoned
- 2007-10-11 UA UAA200904634A patent/UA94484C2/uk unknown
- 2007-10-11 BR BRPI0715580-8A2A patent/BRPI0715580A2/pt not_active IP Right Cessation
- 2007-10-11 AU AU2007324135A patent/AU2007324135B2/en not_active Ceased
- 2007-10-11 JP JP2009532587A patent/JP5298021B2/ja not_active Expired - Fee Related
- 2007-10-11 MX MX2009003774A patent/MX2009003774A/es active IP Right Grant
- 2007-10-11 NZ NZ576032A patent/NZ576032A/en not_active IP Right Cessation
2009
- 2009-04-03 CR CR10705A patent/CR10705A/es unknown
- 2009-04-05 IL IL197937A patent/IL197937A0/en unknown
- 2009-05-08 MA MA31855A patent/MA30876B1/fr unknown
- 2009-05-11 NO NO20091841A patent/NO20091841L/no not_active Application Discontinuation
- 2009-05-12 CO CO09048130A patent/CO6220841A2/es active IP Right Grant
2011
- 2011-02-11 US US13/026,123 patent/US8541552B2/en not_active Expired - Fee Related
- 2011-02-11 US US13/026,069 patent/US8216807B2/en not_active Expired - Fee Related
2012
- 2012-07-06 US US13/543,485 patent/US8642740B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CR10705A (es)	2009-05-07
KR20090078349A (ko)	2009-07-17
RU2009117680A (ru)	2010-11-20
JP5298021B2 (ja)	2013-09-25
US20090285830A1 (en)	2009-11-19
US20130011412A1 (en)	2013-01-10
WO2008063776A3 (en)	2009-03-05
PE20080980A1 (es)	2008-09-02
WO2008063776A2 (en)	2008-05-29
US8216807B2 (en)	2012-07-10
MA30876B1 (fr)	2009-11-02
US20110208673A1 (en)	2011-08-25
NO20091841L (no)	2009-07-13
AU2007324135A1 (en)	2008-05-29
NZ576032A (en)	2012-03-30
IL197937A0 (en)	2011-08-01
CA2665644A1 (en)	2008-05-29
CO6220841A2 (es)	2010-11-19
US8541552B2 (en)	2013-09-24
AU2007324135B2 (en)	2013-06-27
US8642740B2 (en)	2014-02-04
RU2486201C2 (ru)	2013-06-27
US7923011B2 (en)	2011-04-12
MX2009003774A (es)	2009-04-22
EP2084188A2 (en)	2009-08-05
JP2010506568A (ja)	2010-03-04
AR063257A1 (es)	2009-01-14
US20110150865A1 (en)	2011-06-23
CL2007002926A1 (es)	2008-05-16
TWI414531B (zh)	2013-11-11
TW200825101A (en)	2008-06-16
UA94484C2 (uk)	2011-05-10

Legal Events

Date	Code	Title	Description
2015-08-11	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2016-04-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2327 DE 11-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0715580A2 (pt)	2014-06-10	''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO''
BRPI0812878C1 (pt)	2021-05-25	anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor
UA94628C2 (ru)	2011-05-25	Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение
WO2008022295A3 (en)	2008-10-09	Prlr-specific antibody and uses thereof
WO2005116236A3 (en)	2006-11-09	Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
BRPI0606547A2 (pt)	2009-06-30	anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0821447A2 (pt)	2015-06-16	Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
BRPI0905761A2 (pt)	2015-07-14	Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BR112012003809A2 (pt)	2019-09-24	anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BRPI0905076A2 (pt)	2015-07-07	Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BRPI0819211A2 (pt)	2015-06-16	Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
BRPI0811382A2 (pt)	2014-12-09	"anticorpos anti-notch1 nrr isolados, polinucleotídeo, vetor, célula hospedeira, método para produzir um anticorpo anti-notch1 nrr, uso do anticorpo anti-notch1 nrr e composição"
BRPI0610197B8 (pt)	2021-05-25	anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão
WO2008070344A3 (en)	2008-11-20	Compositions and methods for binding sphingosine-1-phosphate
WO2009071696A3 (en)	2009-09-03	Humanized antibody molecules specific for il-31
BRPI0917592A2 (pt)	2015-12-01	"polipeptídeo de região variável de cadeia pesada, anticorpos anti-pd-l1, fragmentos de ligação ao antígeno, composições, ácidos nucleicos, vetor, célula hospedeira, processo para produção de anticorpo anti-pd-l1, artigos de fabricação, método de acentuação da função da célula t, método de tratamento de um distúrbio disfuncional de célula t e uso de uma composição"
BRPI0820270A2 (pt)	2015-06-16	Anticorpo monoclonal, vetor de expressão, célula, conjugado molecular, composição, uso da composição, método para detectar a presença ou ausência de dec-205 em uma amostra biológica, e, uso de um conjugado molecular.
BRPI0815763A2 (pt)	2016-10-11	domínio vhh monomérico derivado de anticorpos anti-vp6 de camelídeo, domínio dimérico, método de imunização, método de detecção de rotavírus, composição, métodos de prevenção e tratamento de infecções por rotavírus.
MX2009006034A (es)	2009-10-12	Anticuerpos antagonistas contra ephb3.
UA99292C2 (uk)	2012-08-10	Антитіло, яке специфічно зв'язується з нейропіліном-2в (nrp2b)
WO2008019326A3 (en)	2008-05-02	Ephb3-specific antibody and uses thereof
EP2196803A4 (en)	2010-12-22	PRE-TREATMENT OF URINE FOR HARN PROTEIN DETERMINATION, URINE PREPARATION PROCEDURES AND HARN PROTEIN PROCEDURE
BRPI1008441A2 (pt)	2016-10-11	anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.
EP1760171A4 (en)	2008-01-23	PRE-TREATMENT AGENT FOR ELECTRODE METAL SEPARATION, METHOD FOR ELECTRICALLY METAL SEPARATION USED THEREOF, AND PRODUCT OF ELECTRICITY METAL SEPARATION